...
首页> 外文期刊>Cornea >Development and application of an in vitro susceptibility test for Acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorhexidine.
【24h】

Development and application of an in vitro susceptibility test for Acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorhexidine.

机译:从角膜炎分离出来的棘阿米巴菌种对聚六亚甲基双胍和氯己定的体外药敏试验的开发和应用。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To develop a reliable in vitro drug susceptibility test against Acanthamoeba isolates and to determine the minimum cysticidal concentration (MCC) of the drug. METHODS: Doubling dilutions of polyhexamethylene biguanide (PHMB) from 3,200 microg/mL to 3.125 microg/mL and chlorhexidine from 3,200 microg/mL to 1.5625 microg/mL were made in Durham tubes and tested against cysts of 19 Acanthamoeba isolates from keratitis. After the exposure to the drugs for 48 hours, the cysts were washed free of drugs by centrifugation. The deposit (cysts) was cultured on nonnutrient agar plates seeded with heat-killed Escherichia coli. The growth of trophozoites from cysts exposed to each of the dilution was recorded by microscopy to estimate the MCC of the drug. RESULTS: The minimum cysticidal concentration of PHMB varied from 25 microg/mL to 100 microg/mL and that of chlorhexidine varied from 1.56 microg/mL to 100 microg/mL. The mean MCC value for PHMB was 55.26 microg/mL and that for chlorhexidine 32.81 microg/mL. Minimum cysticidal concentration 50 (MCC50) of PHMB and chlorhexidine on Acanthamoeba isolates was 50.0 microg/mL and 25.0 microg/mL, respectively. Anti-Acanthamoeba activity of chlorhexidine was higher than that of PHMB and this was statistically significant (p = 0.036). The end point of the results of this method was the detection of the viable cysts undergoing excystment and multiplication of trophozoites with a reproducible and clear-cut estimation of the MCC of PHMB and chlorhexidine. CONCLUSION: The in vitro method described can be used as a standard test for assay of MCC of drugs on Acanthamoeba isolates and to study the susceptibility pattern of newer water-soluble anti-Acanthamoeba drugs.
机译:目的:开发针对棘阿米巴分离株的可靠的体外药敏试验,并确定该药物的最小杀菌浓度(MCC)。方法:在Durham管中制备了从6,200μg/ mL到3.125μg/ mL的聚六亚甲基双胍(PHMB)和从3,200μg/ mL到1.5625μg/ mL的洗必泰的双倍稀释液,并针对19种角膜炎棘阿米巴分离株的囊肿进行了测试。暴露于药物48小时后,通过离心将囊肿洗净以除去药物。将沉积物(囊肿)培养在接种有热灭活大肠杆菌的非营养琼脂平板上。通过显微镜记录暴露于每种稀释液的囊肿中滋养体的生长,以估计药物的MCC。结果:PHMB的最小杀菌浓度在25μg/ mL至100μg/ mL之间,洗必泰的最小杀菌浓度在1.56μg/ mL至100μg/ mL之间。 PHMB的平均MCC值为55.26微克/毫升,洗必泰的平均MCC值为32.81微克/毫升。在棘阿米巴分离物中,PHMB和洗必泰的最小杀菌浓度50(MCC50)分别为50.0 microg / mL和25.0 microg / mL。洗必泰的抗棘阿米巴活性高于PHMB,具有统计学意义(p = 0.036)。该方法结果的终点是检测可滋生的囊肿,并对其进行滋养和滋养体繁殖,并以可重现且清晰的方式估算PHMB和洗必泰的MCC。结论:所描述的体外方法可作为测定棘阿米巴分离株药物MCC的标准测试方法,并用于研究新型水溶性抗棘阿米巴药物的敏感性模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号